Key Takeaways
- • Venture funding for women's health companies collapsed 37.5% year-over-year, declining from $3.2 billion in 2024 to approximately $2 billion in 2025, with biopharma startups experiencing even steeper losses (53% decline from $1.3 billion to $610 million).
- • Women's health companies' share of overall healthcare venture deals contracted from 7.4% to 5.7% between 2024 and 2025, reflecting a broader shift in investor preferences toward established companies with lower risk profiles.
- • Early-stage funding dynamics have fundamentally shifted, with founders now required to demonstrate "tangible early traction" before securing capital, resulting in smaller check sizes and fewer companies advancing to subsequent funding rounds.
- • Despite the 2025 funding decline, 14 women's health startups achieved public market exits in 2025 compared to zero IPOs in 2024, suggesting selective strength in mature-stage exits despite early-stage capital constraints.
- • Industry observers anticipate a potential rebound driven by repositioning of women's health marketing narratives and business models, with potential for more sustainable investment patterns if companies can satisfy heightened investor diligence requirements.
Summary
Women's health venture capital experienced a significant contraction in 2025 following record investment levels the prior year. According to a Silicon Valley Bank report tracking startup funding, total venture capital flowing into women's health companies—including therapeutics, medical devices, and health technologies—declined to approximately $2 billion in 2025 from $3.2 billion in 2024, representing a 37.5% year-over-year drop. The segment's overall share of healthcare venture deals fell to 5.7% from 7.4% during the same period.
Biopharma startups within the women's health sector bore the brunt of this contraction, with venture funding plummeting 53% to $610 million from $1.3 billion. This decline reflects a broader realignment in healthcare investing preferences toward more established companies perceived as lower-risk investments. Megan Scheffel, head of life sciences and healthcare for SVB, characterized this shift as symptomatic of systemic changes across the entire healthcare ecosystem, with early-stage companies facing substantially elevated barriers to capital access.
The funding environment now demands demonstrable proof points before capital deployment. Founders must achieve "tangible early traction" to secure early-stage funding, a threshold that fewer companies are meeting. Consequently, fewer startups are progressing to subsequent funding rounds, forcing early-stage investors to deploy smaller amounts across portfolios. This dynamic creates a structural challenge where women's health startups must accomplish more with reduced capital while competing for investor attention against established healthcare incumbents.
However, selective positive signals emerged in 2025, with 14 women's health startups completing initial public offerings compared to zero IPOs in 2024. This divergence suggests that mature-stage companies with proven business models and market traction remain attractive to public markets, even as venture capital availability for earlier developmental stages has contracted significantly. Industry observers suggest that a potential rebound may emerge if women's health entrepreneurs and investors recalibrate marketing narratives and business model positioning to align with current investor expectations around risk mitigation and demonstrable commercial validation.
Biopharma startups within the women's health sector bore the brunt of this contraction, with venture funding plummeting 53% to $610 million from $1.3 billion. This decline reflects a broader realignment in healthcare investing preferences toward more established companies perceived as lower-risk investments. Megan Scheffel, head of life sciences and healthcare for SVB, characterized this shift as symptomatic of systemic changes across the entire healthcare ecosystem, with early-stage companies facing substantially elevated barriers to capital access.
The funding environment now demands demonstrable proof points before capital deployment. Founders must achieve "tangible early traction" to secure early-stage funding, a threshold that fewer companies are meeting. Consequently, fewer startups are progressing to subsequent funding rounds, forcing early-stage investors to deploy smaller amounts across portfolios. This dynamic creates a structural challenge where women's health startups must accomplish more with reduced capital while competing for investor attention against established healthcare incumbents.
However, selective positive signals emerged in 2025, with 14 women's health startups completing initial public offerings compared to zero IPOs in 2024. This divergence suggests that mature-stage companies with proven business models and market traction remain attractive to public markets, even as venture capital availability for earlier developmental stages has contracted significantly. Industry observers suggest that a potential rebound may emerge if women's health entrepreneurs and investors recalibrate marketing narratives and business model positioning to align with current investor expectations around risk mitigation and demonstrable commercial validation.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.